Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2018 May 9

PMID 29736665

Citations 6

Authors

Hajime Matsushima

Yuko Takami

Tomoki Ryu

Munehiro Yoshitomi

Masaki Tateishi

Yoshiyuki Wada

Hideki Saitsu

Affiliations

Soon will be listed here.

Abstract

Background/aims: Some patients experience very late recurrence of HCC more than 5 years after initial therapy. We aimed to clarify the predictive factors for very late recurrence of HCC in such cases.

Methods: Among 807 HCC patients undergoing surgical resection or ablative therapy with curative intent, the patients who survived for 5 years without any recurrence were reviewed. The prognosis and possible predictive factors for late recurrence were analyzed retrospectively.

Results: A total of 184 patients survived for more than 5 years without recurrence. Among them, 61 patients experienced recurrence, at a median of 6 years after initial therapy. In univariate analysis, the pre-treatment aspartate aminotransferase, alanine aminotransferase, Child-Pugh class, and ALBI grade were not related to recurrence, but those at 5 years after treatment were significantly related to recurrence. By multivariate analysis, an ALBI grade of 2-3 at 5 years was an independent risk factor for recurrence (P < 0.0001). Moreover, variation of the ALBI grade over the 5 years after the initial treatment was significantly related to recurrence-free survival.

Conclusions: The ALBI grade is an effective index of the variation in liver function after curative therapy and may be a useful prognostic factor for the long-term recurrence-free survival of HCC patients.

Citing Articles

Contrast enhanced ultrasound combined with serology predicts hepatocellular carcinoma recurrence: a retrospective observation cohort study.

Tu H, Feng S, Chen L, Huang Y, Zhang J, Wu X Front Oncol. 2023; 13:1154064.

PMID: 37519810 PMC: 10380982. DOI: 10.3389/fonc.2023.1154064.

Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Yao L, Chen Z, Feng Z, Diao Y, Li C, Sun H Ann Surg Oncol. 2022; .

PMID: 35192156 DOI: 10.1245/s10434-022-11454-y.

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.

Kudo M, Galle P, Brandi G, Kang Y, Yen C, Finn R JHEP Rep. 2021; 3(2):100215.

PMID: 33392490 PMC: 7772786. DOI: 10.1016/j.jhepr.2020.100215.

The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection.

Lin C, Lin C, Wang C, Chen C, Hu T, Hung C World J Surg. 2019; 44(1):247-257.

PMID: 31559485 DOI: 10.1007/s00268-019-05197-3.

Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C.

Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M Hepatol Res. 2019; 49(7):731-742.

PMID: 30892804 PMC: 6851801. DOI: 10.1111/hepr.13333.

References

Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y . Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg. 2009; 16(3):359-66. DOI: 10.1007/s00534-009-0069-7. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Honda K, Seike M, Oribe J, Endo M, Arakawa M, Syo H . Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy. World J Hepatol. 2016; 8(13):597-604. PMC: 4858624. DOI: 10.4254/wjh.v8.i13.597. View

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio G . Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-35. PMC: 1448919. DOI: 10.1097/01.sla.0000197706.21803.a1. View

Toyoda H, Lai P, OBeirne J, Chong C, Berhane S, Reeves H . Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer. 2016; 114(7):744-50. PMC: 4984858. DOI: 10.1038/bjc.2016.33. View

Fan S, Poon R, Yeung C, Lam C, Lo C, Yuen W . Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg. 2011; 98(9):1292-300. DOI: 10.1002/bjs.7583. View

Zheng J, Kuk D, Gonen M, Balachandran V, Kingham T, Allen P . Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Ann Surg Oncol. 2016; 24(5):1358-1366. PMC: 5609806. DOI: 10.1245/s10434-016-5713-2. View

Baker E, Thompson K, McKillop I, Cochran A, Kirks R, Vrochides D . Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients. J Gastrointest Oncol. 2017; 8(2):337-346. PMC: 5401852. DOI: 10.21037/jgo.2016.09.06. View

Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Mikagi K . Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A. J Gastrointest Surg. 2017; 21(6):957-966. DOI: 10.1007/s11605-017-3394-1. View

10.

Matsumoto K, Yoshimoto J, Sugo H, Kojima K, Futagawa S, Matsumoto T . Relationship between the histological degrees of hepatitis and the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis C. Hepatol Res. 2002; 23(3):196-201. DOI: 10.1016/s1386-6346(01)00180-2. View

11.

Huang Z, Liang B, Xiong M, Zhan D, Wei S, Wang G . Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol. 2012; 19(8):2515-25. DOI: 10.1245/s10434-012-2269-7. View

12.

Waked I, Berhane S, Toyoda H, Chan S, Stern N, Palmer D . Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017; 116(4):448-454. PMC: 5318968. DOI: 10.1038/bjc.2016.423. View

13.

Ryu T, Takami Y, Tsutsumi N, Tateishi M, Mikagi K, Wada Y . Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism. Surg Today. 2016; 47(5):548-554. DOI: 10.1007/s00595-016-1411-8. View

14.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

15.

Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S . Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol. 2015; 21(4):1207-15. PMC: 4306165. DOI: 10.3748/wjg.v21.i4.1207. View

16.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7. DOI: 10.1016/s0168-8278(02)00360-4. View

17.

Shen J, Li C, Wen T, Yan L, Li B, Wang W . Liver transplantation versus surgical resection for HCC meeting the Milan criteria: A propensity score analysis. Medicine (Baltimore). 2016; 95(52):e5756. PMC: 5207585. DOI: 10.1097/MD.0000000000005756. View

18.

Pinato D, Sharma R, Allara E, Yen C, Arizumi T, Kubota K . The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2016; 66(2):338-346. DOI: 10.1016/j.jhep.2016.09.008. View

19.

Seyama Y, Kokudo N . Assessment of liver function for safe hepatic resection. Hepatol Res. 2009; 39(2):107-16. DOI: 10.1111/j.1872-034X.2008.00441.x. View

20.

Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H . Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996; 83(9):1219-22. View